Modern issues of life quality research in haematology

Quality of life assessment before, during and after treatments is a valid, reliable and simple way to evaluate functioning of patients with malignant blood diseases from patient’s perspective. Systemic monitoring of treatment outcomes in hematological patients presumes the use of dichotomous model which includes evaluation of clinical response and quality of life treatment response. Clinical response is based on objective data, namely biological and clinical parameters, quality of life treatment response – on subjective data, coming directly from the patient. Within the national multicenter prospective study «Quality of life parameters and symptom profile in chronic myeloid leukemia patients with imatinib resistance or intolerance during second line treatment» clinical response and quality of life treatment response were evaluated. 55 chronic myeloid leukemia patients with imatinib resistance or intolerance have been included in the program. Hematological and cytogenetic response to dasatinib treatment was obtained in the majority of patients. Quality of life improvement during treatment was registered as well. The majority of patients exhibited quality of life treatment response in terms of improvement or stabilization. The preliminary data obtained demonstrate the efficacy of dasatinib second line therapy in chronic myeloid leukemia patients both from physician’s and patient’s perspective.

1.   ASCO. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines // J. Clin. Oncol. 1996. 14. (3). 671–679.

2.   US Food and Drug Administration: Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from webcite U.S. FDA, Clinical/Medical; 2009.

3.   Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине (3-е изд., перераб. и доп.) / Ред. Ю.Л. Шевченко. М.: РАЕН, 2012. 528 с.

4.   Gorodokin G., Novik A. Quality of cancer care // Ann. Oncol. 2005. 16. (6). 991.

5.   Moskowitz C.H. An update on the management of relapsed and refractory Hodgkin’s Lymphoma // Semin. Oncol. 2004. 31. 54–59.

6.   Moskowitz C.H. Outcome of patients with primary refractory HD treated with high dose combined modality therapy and ASCT // Br. J. Haematol. 2004. 124. 645–652.

7.   Tannock I.F. Treating the patient, not just the cancer // N. Engl. J. Med. 1987. 317. 1534–1535.

8.   Ионова Т.И., Рыков И.В., Калядина С.А. Популяция больных гемобластозами гетерогенна по интегральному показателю качества жизни // Вестн. Межнац. центра исследования качества жизни. 2007. (9–10). 99–108.

9.   Bertero C., Eriksson B.E., Ek A.C. Explaining different profiles in quality of life experiences in acute and chronic leukemia // Cancer Nurs. 1997. 20. (2). 100–104.

10. Coates A.S., Porzsolt F., Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ–C30 scores in patients with advanced malignancy // Eur. J. Cancer. 1997. 33. 1025–1030.

11. Dancey J., Zee B., Osoba D. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy // Can. Med. Assoc. J. 1996. 10. 225–230.

12. Gulbrandsen N., Hjermstad M.J., Wisloff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences // Eur. J. Haematol. 2004. 72. (3). 172.

13. Wisloff F., Hellstrom-Lindberg E., Lindberg G. et al. A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin and G–CSF – significant effects on quality of life // Br. J. Haematol. 2003. 120. 1037–1046.

14. Hwang S.S., Scott C.B., Chang V.T. et al. Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress // Cancer Invest. 2004. 22. 678–687.

15. Jerkeman M., Kaasa S., Hjermstad M. et al. Health–related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial // Med. Oncol. 2001. 18. (1). 85–94.

16. Novik A.A., Ionova T.I., Povzun A.S. et al. Quality of life of in patients with different types of leukemia // Qual. Life Res. 2000. 9. (3). 294.

17. Novik A., Ionova T., Kishtovich A. Heterogeneity of new lymphoma patients in terms of quality of life parameters // Blood. 2003. 22. 302.

18. Sedman A.D., Porteney R., Yao T.J. et al. Quality of life in Phase II Trials: a study of methodology and predictive value in patients with advance breast cancer treated with Paclitaxel plus granulocyte colony stimulating factor // J. Nat. Cancer Inst. 1995. 87. 1316–1322.

19. Guidelines. Patient-reported outcomes in hematology. Eds. A. Novik, S. Salek, T. Ionova. Genoa: Forum service editore, 2012.

20.          Ионова Т.И. Концептуальные и методологические аспекты исследования качества жизни в онкогематологии: автореф. дис. … докт. биол. наук. СПб., 2009.

Ionova T.I. – professor of the chair for haematology and cell therapy, head of the department for quality of life monitoring, e-mail: tation16@gmail.com